What is immunoactive prophylaxis and how is it used to prevent recurrent urinary tract infections in a woman requiring an SGLT2 inhibitor for cardiovascular and renal protection?

What is Immunoactive Prophylaxis?

Immunoactive prophylaxis refers to the use of bacterial lysates (vaccines containing inactivated bacterial components) to stimulate the immune system and prevent recurrent urinary tract infections (rUTIs) without using antibiotics. This approach works by enhancing host immune defenses against uropathogens, particularly E. coli, which causes approximately 64% of UTIs 1.

Mechanism and Products

Immunoactive prophylaxis utilizes two main delivery routes:

• Oral bacterial lysates (e.g., OM-89): Contain inactivated bacterial components that stimulate systemic immune responses
• Vaginal vaccines (e.g., Uromune®): Deliver bacterial antigens locally to the urogenital mucosa

These products train the immune system to recognize and respond more effectively to common uropathogens, reducing UTI frequency by approximately 39% on average 2.

Guideline-Based Recommendations

The 2024 European Association of Urology guidelines provide a STRONG recommendation to use immunoactive prophylaxis to reduce recurrent UTI in all age groups 3. This represents a significant endorsement, placing immunoactive prophylaxis alongside vaginal estrogen (in postmenopausal women) and methenamine hippurate as strongly recommended non-antibiotic interventions.

The 2025 AUA/CUA/SUFU guidelines similarly emphasize expanding non-antibiotic options for UTI prophylaxis, reflecting a paradigm shift away from routine antimicrobial use due to concerns about antibiotic resistance and collateral damage 4.

Clinical Efficacy

Recent data from a large cohort of 1,104 women treated with Uromune® vaccine demonstrated impressive efficacy 1:

• 91.7% efficacy at 3 months (defined as 0-2 UTIs during follow-up)
• 82.3% efficacy at 6 months
• 57.6% efficacy at 12 months

Patients with 3-4 baseline UTIs (rather than ≥5) achieved significantly better outcomes: 97.7% efficacy at 3 months and 64.7% at 12 months (p < 0.05) 1. This suggests earlier intervention yields superior results.

Application in Women Requiring SGLT2 Inhibitors

For women requiring SGLT2 inhibitors for cardiovascular and renal protection, immunoactive prophylaxis offers a particularly valuable strategy:

Why This Matters

SGLT2 inhibitors increase urinary glucose excretion, theoretically raising UTI risk. However, large randomized trials show no significantly increased risk of bacterial (noncandida) UTI with SGLT2 inhibitors 5, 6. The primary genitourinary concern is candida infections, not bacterial UTIs 7, 8.

Critical Clinical Point

Routine discontinuation of SGLT2 inhibitors due to UTIs is NOT recommended 9. Permanent discontinuation results in rapid loss of cardiorenal benefits—these drugs reduce cardiovascular and renal morbidity and mortality 9, 10. Most genitourinary infections are mild-to-moderate and respond to standard antimicrobial treatment without requiring drug cessation 9.

Optimal Strategy

For women on SGLT2 inhibitors experiencing rUTIs, implement immunoactive prophylaxis as first-line prevention rather than discontinuing the SGLT2 inhibitor 3. This approach:

1. Maintains the life-saving cardiovascular and renal benefits of SGLT2 inhibitors
2. Addresses rUTI through immune enhancement rather than continuous antibiotics
3. Avoids antibiotic resistance and collateral damage
4. Provides sustained protection (particularly effective in first 6 months)

Treatment Algorithm

Step 1: Confirm rUTI diagnosis via urine culture 3

Step 2: Initiate immunoactive prophylaxis (strong recommendation) 3

• Oral bacterial lysate (OM-89) OR vaginal vaccine (Uromune®)
• Continue SGLT2 inhibitor unless severe/persistent contraindication develops 9

Step 3: If immunoactive prophylaxis fails after 6-12 months, consider:

• Methenamine hippurate (strong recommendation for women without urinary tract abnormalities) 3
• Vaginal estrogen if postmenopausal (strong recommendation) 3
• Probiotics or cranberry products (weak recommendations) 3

Step 4: Reserve continuous antimicrobial prophylaxis only when non-antimicrobial interventions have failed 3

Important Caveats

• Timing matters: Patients with fewer baseline UTIs (3-4 vs ≥5) benefit more from immunoactive prophylaxis 1
• Duration: Peak efficacy occurs in the first 6 months; consider booster cycles for sustained effect 2
• Not for complicated UTIs: This approach applies to uncomplicated rUTI in otherwise healthy women without anatomic/functional urinary tract abnormalities, immunocompromise, or indwelling catheters 4
• SGLT2 inhibitor continuation: Recent data show SGLT2 inhibitors initiated even after UTI are associated with lower mortality and kidney complications compared to DPP-4 inhibitors 6, reinforcing the importance of maintaining therapy